About this item:

15 Views | 3 Downloads

Author Notes:

Correspondence should be addressed to: James R. Cerhan, M.D., Ph.D., Mayo Clinic, 200 First Street SW, Rochester, MN 55905, Phone: 507.538.0499, Fax: 507.226.2478, cerhan.james@mayo.edu.

Please see publication for full list of author contributions.

We thank C. Allmer, E. Angelucci, A. Bigelow, S. Buehler, K. Butterbach, A. Chabrier, J.M. Conners, M. Corines, M. Cornelis, K. Corsano, H. Dykes, L. Ershler, A. Gabbas, R.P. Gallagher, R.D. Gascoyne, P. Hui, L. Irish, L. Jacobus, L. Klareskog, A.S. Lai, J. Lunde, M. McAdams, R. Montalvan, L. Padyukov, M. Rais, T. Rattle, L. Rigacci, K. Snyder, G. Specchia, M. Stagner, G. Thomas, C. Tornow, G. Wood, and M. Yang.

The authors declare no competing financial interests

Subjects:

Research Funding:

The overall GWAS project was supported by the intramural program of the US National Institutes of Health/National Cancer Institute.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Genetics & Heredity
  • NON-HODGKIN-LYMPHOMA
  • CHRONIC LYMPHOCYTIC-LEUKEMIA
  • NECROSIS-FACTOR TNF
  • FOLLICULAR LYMPHOMA
  • COMMON VARIANTS
  • RAL GTPASES
  • RISK
  • CANCER
  • TUMORIGENESIS
  • POPULATION

Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma

Show all authors Show less authors

Tools:

Journal Title:

Nature Genetics

Volume:

Volume 46, Number 11

Publisher:

, Pages 1233-1238

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma subtype and is clinically aggressive. To identify genetic susceptibility loci for DLBCL, we conducted a meta-analysis of 3 new genome-wide association studies (GWAS) and 1 previous scan, totaling 3,857 cases and 7,666 controls of European ancestry, with additional genotyping of 9 promising SNPs in 1,359 cases and 4,557 controls. In our multi-stage analysis, five independent SNPs in four loci achieved genome-wide significance marked by rs116446171 at 6p25.3 (EXOC2; P = 2.33 × 10 '21), rs2523607 at 6p21.33 (HLA-B; P = 2.40 × 10 '10), rs79480871 at 2p23.3 (NCOA1; P = 4.23 × 10 '8) and two independent SNPs, rs13255292 and rs4733601, at 8q24.21 (PVT1; P = 9.98 × 10 '13 and 3.63 × 10 '11, respectively). These data provide substantial new evidence for genetic susceptibility to this B cell malignancy and point to pathways involved in immune recognition and immune function in the pathogenesis of DLBCL.

Copyright information:

© 2014 Nature America, Inc. All rights reserved.

Export to EndNote